Clostridium difficile is one of the most common causes of bacterial diarrhea and colitis among hospitalized patients. The organism cannot compete successfully with the normal microflora of the adult colon but can grow to high numbers when the colonic flora has been disturbed by antibiotic treatments (35, 45) . C. difficile then keeps the colonic flora from reestablishing itself by producing an enterotoxin, toxin A, which causes destruction of the colonic epithelium, resulting in fluid secretion into the intestine (25, 27) . A second toxin produced by C. difficile, toxin B, has no effect on undisturbed intestinal epithelium but is an extremely active cytotoxin on nonepithelial cells (1, 25, 27, 29, 40, 41) . This toxin may gain access to the underlying cells through the destructive action of toxin A on the epithelial cells (27) . Hamsters are the most susceptible laboratory animal to this disease, and in these animals the two toxins seem to act synergistically. Toxin B alone has no effect when given orally to hamsters but kills them when it is combined with sublethal amounts of toxin A (27) .
An enterotoxin must bind to the intestinal epithelial cells, and toxins often accomplish this by binding to specific carbohydrate structures on the membrane of the epithelial cells. Previous work in this laboratory has shown that toxin A binds to a trisaccharide (Galal-3GaI1-4GlcNAc) which occurs in large amounts on the intestinal cells of hamsters (6, 22) . Hamsters can be protected from this disease by immunizing them with a recombinant peptide which contains the carbohydrate-binding portion of toxin A (8) . This recombinant protein contains repeating amino acid domains which bind multiple copies of the trisaccharide receptor for the toxin (8, 33) . Recently, we have shown that cell lines which express large amounts of this carbohydrate on their cell membranes are more sensitive to the cytotoxic action of toxin A than are other cell lines (42, 44) . This evidence led us to speculate that Galal-3GalI1-4GlcNAc was the biological receptor for toxin A in humans as well as hamsters.
A search of the literature revealed that there was a problem with this postulate. Normal human cells do not express this trisaccharide (11, 13) . Furthermore, most people produce antibodies against this carbohydrate (12) . Pre-* Corresponding author. liminary experiments showed that toxin A did bind to human intestinal epithelium; therefore, we started to test for the binding of toxin A to carbohydrate structures that have been reported to exist on human intestinal mucosa. The first structure we tested was a carbohydrate (Galpl-4 GlcNAc) which appeared to be conformationally similar to the reported receptor for toxin A (Galal-3Gal3l-4GlcNAc). We found that toxin A bound to this carbohydrate and two other related oligosaccharides, all of which exist on human intestinal epithelial cells.
MATERIALS AND METHODS
Biochemicals. Carbohydrates isolated from human milk and chemically conjugated to human serum albumin (HSA) were kindly provided by Howard Krivan of BioCarb Chemicals or were purchased from BioCarb Chemicals (Lund, Sweden). See Table 1 for a description of the oligosaccharides and their names. In order to determine if toxin A from C. difficile bound to these oligosaccharide-HSA conjugates, we performed two assays: crossed immunoelectrophoresis (IEP) and enzyme-linked immunosorbent assay (ELISA) (as described below). We also assayed the binding of toxin A to bovine thyroglobulin (Sigma Chemical Co., St. Louis, Mo.), which contains Galal-3Gal,B1-4GlcNAc (37) , and to the following human proteins, both of which contain the X antigen (4, 30) : secretory component (Chemicon, Temecula, Calif.) and carcinoembryonic antigen (CEA) (Calbiochem, San Diego, Calif.).
Toxin purification. C. difficile VPI 10463 was grown in dialysis cultures (39) . A culture filtrate was prepared by filtering the contents of the dialysis sac with a 0.45-,um-poresize filter. Toxin A was purified from the culture filtrate by affinity chromatography, using immobilized bovine thyroglobulin (23) . The toxin was determined to be homogeneous by procedures previously described (39) . The concentration of toxin A was estimated by the method of Bradford (3) with bovine gamma globulin as the standard. Antiserum. Antiserum to culture filtrate of C. difficile was prepared in goats (9) . Affinity-purified antibody to toxin A was prepared as previously described (28) . The affinitypurified antibody to the toxin was biotinylated with biotina-midocaproate N-hydroxysuccinimide ester (Sigma) (16) . The biotin-antibody conjugate was used at a 1:1,000 dilution.
LEP. The binding of toxin A to glycoproteins was assayed by IEP (22) by mixing 100 ,ug of toxin A with 500 ,ug of glycoprotein per ml and incubating on ice for 10 min before loading on the gel. The migration of toxin A with the glycoprotein was compared with the migration of toxin A alone. Interpretation of the results is based on the fact that toxin A normally migrates slowly in IEP. If toxin A binds to a glycoprotein that migrates rapidly in IEP, then the bound toxin will be pulled by the more rapidly migrating glycoprotein, thus causing an increase in the migration of toxin A in IEP. If toxin A does not bind to the glycoprotein, then the mixture does not affect the migration of the toxin.
ELISA. ELISAs were performed in Immulon II 96-well microtiter plates (Dynatech Laboratories, Inc., Alexandria, Va.). Each well was coated with 150 RI of 1:2 serially diluted glycoprotein, starting at 20 ,ug of glycoprotein per ml of 50 mM carbonate buffer (pH 9.6). Plates were incubated for 16 h at 4°C and then washed twice with PBS-T (0.8% NaCl, 0.02% KH2PO4, 0.22% Na2HPO4, 0.02% KC1, 0.05% Tween 20, 0.02% NaN3 [pH 7.4]). The plates were blocked with 0.5% casein in 100 mM Tris-150 mM NaCl (pH 7.0) for 1 h at 22°C and then were washed twice with PBS-T. To each well was added 100 ,ul of toxin A at 10 pug/ml in PBS-T. The plates were incubated at either 4 or at 37°C for 3 h. After this step, all buffers were at 4°C and all treatments were performed in a 4°C cold room, unless otherwise stated. The plates were washed twice with PBS-T, and 100 ,ul of a 1:1,000 dilution of biotinylated antibody to toxin A in PBS-T was added to each well and incubated for 1 h. The plates were washed twice with PBS-T, and 100 ,ld of 0.1-U/ml alkaline phosphatase conjugated to avidin (Sigma) was added to each well. The plates were incubated for 1 h and washed twice with PBS-T. Then the plates were moved to room temperature and 100 ,u of para-nitrophenylphosphate (1 mg/ml) in 100 mM diethanolamine buffer (pH 9.8) was added to each well. All assays were developed for 90 min at room temperature before the A405 was read. Control wells included wells without toxin A and/or without glycoprotein. The lized Galal-3Gal1-4GlcNAc (23) ; however, the X antigen was used in place of Galal-3GalPi1-4GlcNAc. Culture filtrate was concentrated fivefold on a MiniCon concentrator (Amicon, Danvers, Mass.), and then 25 ,ul of this was mixed with a 20-,ul pellet of latex beads containing the X antigen. This was incubated on ice for 10 min, and then the latex beads were pelleted by centrifugation. The supernatant was saved, and the pellet was washed three times with ice-cold TBS.
The latex beads were then warmed to 37°C in 25 ,ll of TBS and then pelleted by centrifugation. Each step of the isolation was monitored using IEP with 5 ,ul of sample in the first dimension and 100 ,u of antiserum to culture filtrate of C. difficile in the second dimension.
RESULTS
Examination of molecular models suggested to us that the X antigen (Gal1-4[Fucal-3]GlcNAc) was conformationally similar to the previously identified receptor Galal-3Galp1-4GlcNAc. Polysaccharides that contain the X antigen are present on the naturally occurring glycoproteins CEA and the secretory component of human antibodies (4, 30) . Mixing these proteins with toxin A caused an alteration in the migration of toxin A in an electric field; this was most easily observed in IEP. We then confirmed by ELISA that toxin A was binding to these two glycoproteins. This assay showed that toxin A was binding at 4°C but not at 37°C (Fig. 1) . Similar results were obtained with bovine thyroglobulin, which contains the previously described trisaccharide receptor (Gala1-3Gal1-4GlcNAc) .
Although the binding of toxin A to these proteins suggested that the toxin was binding to the X antigen, there was a possibility that toxin A was binding to other carbohydrate structures shared by these two glycoproteins (e.g., BiAO, see Table 1 for structure; 4, 30). The conformation of the trisaccharide that defines the X antigen is part of the pentasaccharide LNF III. Therefore, we tested the binding of toxin A to the purified pentasaccharide which had been conjugated to HSA. The LNF III-HSA conjugate also altered the migration of toxin A in IEP (data not shown) and bound toxin A in an ELISA (Fig. 1) LNF III contains two carbohydrates more than the X antigen, which is defined by a trisaccharide. To determine if toxin A would bind to the X antigen alone, we tested for agglutination of latex beads to which this trisaccharide had been attached. Toxin A agglutinated these coated beads, and the beads specifically removed the toxin from culture filtrate at 4°C. Warming the beads to 37°C eluted the purified toxin (Fig. 2) .
To further define the minimal carbohydrate structure that bound toxin A, we assayed the binding of toxin A to the i antigen conjugated to HSA. This tetrasaccharide is similar to LNF III but lacks the al-3-linked fucose. As has been previously reported (6), we found that the i antigen did not bind toxin A (Table 1) . Unexpectedly, we found that toxin A did bind to the branched form of this antigen, which is called the I antigen (Fig. 1) . The I antigen contains two type 2 core structures (GalI,1-4GlcNAc) per oligosaccharide ( Table 1) . The toxin did not bind to any of the oligosaccharides we tested that contain the similar type 1 core structure (Gal1l-3GlcNAc [ Table 1 ]).
We then tested the Y antigen, which is similar to the X antigen except that it contains an additional otl-2-linked fucose. Y antigen conjugated to HSA altered the migration of toxin A in IEP (Fig. 3) , and in an ELISA toxin A bound to this antigen in a temperature-dependent manner (Fig. 4) Gal1P-4GlcNAcP1-3Gal1P-4(Glc) Yes 6 Gal1-4G1cNAcpl' BiAO ---Gall3l-4GlcNAcp1-2Manal-3Manpl-4(GlcNAc) No 6 GaIlP-4GlcNAcp1-2Manal' aThe names used in this table are the conventional designations used for these carbohydrates.
b The X and Y antigens are also referred to as the Lewis X (Le') and Lewis Y (Ley) antigens, respectively. We use the designation X and Y because theses antigens are not actually members of the Lewis blood group (43) . The X antigen is also designated by several other names, including My-1 (19), VEP8-and VEP9-antigen (15) , and stage-specific embryonic antigen 1 (14) .
c Parentheses around a carbohydrate indicate that the carbohydrate was chemically modified during the linking of the oligosaccharide to HSA. After all, toxin A binds to the I antigen, X antigen, and 1 1 1 -HSA (37°C) Galal-3GalIP-4GlcNAc equally and toxin A appears to use 15 20 Galol-3Gal11-4GlcNAc as a receptor on hamster intestinal (22 branes that are characteristic of pseudomembranous colitis. 
Downloaded from
Furthermore, toxin A causes granulocytes to release factors that can cause intestinal secretion and enteritis (31, 32). This had led some researchers to speculate that toxin A is not directly active on intestinal epithelium but that the factors released from the granulocytes cause the tissue damage and diarrhea associated with toxin A in vivo (41) . We believe toxin A does act directly on intestinal epithelium, because toxin A is toxic to cell lines in vitro that are physiologically similar to intestinal epithelium (17) . Even so, we agree that some of the symptoms associated with pseudomembranous colitis may be due to the factors released by the granulocytes. These factors may add to the tissue damage associated with toxin A, thus increasing the severity of the disease. Most human infants apparently are insensitive to toxin A, since they can be colonized by toxigenic C. difficile with no ill effects (2, 7, 34) . Previously, this laboratory proposed that the insensitivity of infants to toxin A may be due to either the lack of a receptor for toxin A or a low density of the receptor (5, 22) . However, human infants express the Y antigen on their intestinal epithelium (20, 21) and the Y antigen binds toxin A at 37°C. Therefore, our data conffict with the postulate that infants are insensitive to toxin A because they lack a receptor for the toxin.
In summary, we have found that toxin A binds to three carbohydrate antigens (I, X, and Y) that are present on human intestinal cells. These antigens may be receptors for toxin A on human intestinal mucosa.
